106 related articles for article (PubMed ID: 16243564)
21. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques.
McCormick-Davis C; Zhao LJ; Mukherjee S; Leung K; Sheffer D; Joag SV; Narayan O; Stephens EB
Virology; 1998 Sep; 248(2):275-83. PubMed ID: 9721236
[TBL] [Abstract][Full Text] [Related]
22. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
23. Is the Nef protein of HIV-1 required for pathogenesis?
Miller MD; Greene WC
Trends Microbiol; 1996 May; 4(5):171-2; discussion 173. PubMed ID: 8727595
[No Abstract] [Full Text] [Related]
24. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
[TBL] [Abstract][Full Text] [Related]
25. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
26. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.
Cosma A; Nagaraj R; Bühler S; Hinkula J; Busch DH; Sutter G; Goebel FD; Erfle V
Vaccine; 2003 Dec; 22(1):21-9. PubMed ID: 14604567
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
[TBL] [Abstract][Full Text] [Related]
28. Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus.
Gardner MB; Luciw PA; Sawai ET; Marthas ML; Miller CJ; McChesney MB; Lerche NW; Pedersen NC
AIDS Res Hum Retroviruses; 1996 Mar; 12(5):399-401. PubMed ID: 8882318
[No Abstract] [Full Text] [Related]
29. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
31. Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B.
Rodríguez AM; Turk G; Pascutti MF; Ferrer F; Nájera JL; Mónaco D; Esteban M; Salomón H; Calamante G; Gherardi MM
Virus Res; 2009 Dec; 146(1-2):1-12. PubMed ID: 19715734
[TBL] [Abstract][Full Text] [Related]
32. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
33. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
34. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides.
Bourgault I; Chirat F; Tartar A; Lévy JP; Guillet JG; Venet A
J Immunol; 1994 Mar; 152(5):2530-7. PubMed ID: 8133061
[TBL] [Abstract][Full Text] [Related]
35. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
36. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection.
Wildum S; Schindler M; Münch J; Kirchhoff F
J Virol; 2006 Aug; 80(16):8047-59. PubMed ID: 16873261
[TBL] [Abstract][Full Text] [Related]
37. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
38. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
[TBL] [Abstract][Full Text] [Related]
39. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
[TBL] [Abstract][Full Text] [Related]
40. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
